Lexeo Therapeutics, Inc. (LXEO)
NASDAQ: LXEO · IEX Real-Time Price · USD
13.14
-1.36 (-9.38%)
May 10, 2024, 4:30 PM EDT - Market closed
Lexeo Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Lexeo Therapeutics stock have an average target of 21.2, with a low estimate of 19 and a high estimate of 24. The average target predicts an increase of 61.34% from the current stock price of 13.14.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 12, 2024.
Analyst Ratings
The average analyst rating for LXEO stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Maintains $22 → $24 | Buy | Maintains | $22 → $24 | +82.65% | Mar 12, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Initiates $23 | Strong Buy | Initiates | $23 | +75.04% | Nov 28, 2023 |
| Leerink Partners | Leerink Partners | Buy Initiates $19 | Buy | Initiates | $19 | +44.60% | Nov 28, 2023 |
| RBC Capital | RBC Capital | Buy Initiates $22 | Buy | Initiates | $22 | +67.43% | Nov 28, 2023 |
| Stifel | Stifel | Strong Buy Initiates $20 | Strong Buy | Initiates | $20 | +52.21% | Nov 28, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-3.40
from -12.40
EPS Next Year
-3.76
from -3.40
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | 59.9M | 337.1M |
| Avg | n/a | n/a | n/a | 40.5M | 220.7M |
| Low | n/a | n/a | n/a | 14.7M | 109.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 731.5% |
| Avg | - | - | - | - | 444.4% |
| Low | - | - | - | - | 170.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.45 | -2.06 | -1.93 | -7.69 | -5.16 |
| Avg | -3.40 | -3.76 | -4.44 | -7.47 | -5.01 |
| Low | -4.23 | -5.56 | -6.72 | -7.17 | -4.81 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.